The dark chocolate biscuit that could help you lose weight
Scientists have created a biscuit that contains a special ingredient to help people lose weight.
That's according to an early study that added a new ingredient to confectionary in an attempt to make people feel less hungry.
The team from the University of Eastern Piedmont in Italy presented their preliminary findings at the European Congress on Obesity in Malaga, Spain.
Researchers said they added a bitter compound from the Artemisia absinthium plant, also known as wormwood, to an ordinary dark chocolate biscuit.
A test on 11 healthy people revealed the bitter ingredient made participants feel fuller.
Participants were given two different formulas, one cocoa biscuit and the another which had an enriched bitter flavour using 16 per cent Artemisia absinthium extract.
Food cravings were then measured using a questionnaire on how full they felt after eating.
Researchers found those who ate the special biscuits felt less hungry and saw an increase in satiety hormones in comparison to those who ate the plain cocoa biscuit.
The bitter taste in the added compound regulates how the body releases the hunger hormone ghrelin and GLP-1, a hormone that also regulates blood sugar, appetite and digestion, study authors explained.
It's also the same hormone targeted with weight-loss jabs like Wegovy and diabetes treatment like Ozempic.
This hormone reduces food cravings and slows down how quickly food is digested.
This can reduce the rate glucose is absorbed into the bloodstream. As a result, it makes those who take it feel fuller for longer, eat less and lose weight.
Study author Dr Flavia Prodam explained that all the people who ate the bitter biscuit reported lower hunger levels before dinner, but not at any other time of the day.
The biscuits which have been described as being 'very tasty' could be sold commercially to help people lose weight, according to Dr Prodam.
The team now plans to launch a clinical trial to investigate how the biscuit affects food intake in obese patients.
Dr Prodam said: 'This is an important thing to target because we need to educate people to eat less but there is a lot of failure. The emotional part of eating is important in obesity.
'People want comfort foods, so having one that decreases hunger could be a good strategy.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
NY man alleges vision loss after taking Ozempic: Details
The Brief A 48-year-old man from Suffolk County blames Ozempic for partial vision loss in both eyes. He, along with over 30 others who are suffering from the same side effect, are suing Ozempic's manufacturer. The manufacturer, Novo Nordisk, states they believe "the benefit-risk profile of semaglutide remains unchanged." LONG ISLAND - Michael, a 48-year-old from Suffolk County, is suing Ozempic's manufacturer for partial loss of vision. What we know Michael, who opted out of sharing his surname, says that the loss of sight began after his endocrinologist recommended he switch from Metformin to Ozempic to manage his type 2 diabetes. Michael told FOX 5 NY's Jodi Goldberg that he lost 10 pounds, but also some vision in both eyes. "From the bottom right side of my eye… if I close the left eye, faces get blurry, I can't read my cell phone." He claims he had 20/20 vision before taking Ozempic. Michael was diagnosed with NAION (Non-arteritic Anterior Ischemic Optic Neuropathy), which is essentially a stroke of the eye – it presents as an acute but painless loss of vision in one eye. No treatment for NAION currently exists. One of the most recognized risk factors for NAION is diabetes. However, two recent studies – one from the JAMA Network and the other out of Denmark – suggest there could be a link between the condition and taking semaglutide, which is the active ingredient in Ozempic. Jason Goldstein of Parker Waichman LLP, a personal injury, mass tort and environmental law firm, has filed a multimillion dollar lawsuit against Novo Nordisk, the manufacturer of Ozempic and Wegovy, a similar medication. Goldstein is representing more than 30 clients from 10 states suffering from the same side effect, including Michael. "This lawsuit is about holding Novo Nordisk responsible for not warning doctors and their patients this condition could develop," Goldstein said. Dig deeper Over the past decade, the U.S. Food and Drug Administration (FDA) has recalled over 14,000 drugs; rare side effects can be missed during clinical trials and may not be discovered until later on. Goldberg spoke to Dr. Chetna Bakshi about how common reactions to medications like Ozempic could be. Bakshi's take is that more research is necessary. "These medications come out, people take them, and it's not until 10 or 15 years later that we find other complications that weren't apparent in the initial clinical trials." The other side A spokesperson for Novo Nordisk gave FOX 5 this statement: "Patient safety is a top priority for Novo Nordisk, and we take all reports about adverse events from use of our medicines very seriously. After a thorough evaluation of studies from the University of Southern Denmark and Novo Nordisk's internal safety assessment, Novo Nordisk is of the opinion that the benefit-risk profile of semaglutide remains unchanged." Goldstein's response: "It was a drug you were taking, that there were other options on the market, and no one warned you this could happen." The Source This article includes reporting from FOX 5 NY's Jodi Goldberg, as well as two medical studies from the JAMA Network and a Danish-Norwegian cohort.
Wall Street Journal
5 hours ago
- Wall Street Journal
How Ozempic's Maker Lost Its Grip on the Obesity Market It Created
In 2023, Novo Nordisk NVO -2.61%decrease; red down pointing triangle was the most valuable company in Europe, surpassing LVMH on the back of soaring demand for Ozempic and Wegovy. Today, the Danish company has lost its grip on the anti-obesity market it carved out. The company has lost market share amid production missteps and a bungled rollout of Wegovy that led to shortages. Its U.S. rival Eli Lilly LLY -0.80%decrease; red down pointing triangle—initially in the rearview mirror—has been proven to have the more effective weight-loss drug and a more promising pipeline of next-generation treatments. Novo Nordisk's research-and-development machine has disappointed, and a key marketing strategy was slow to get off the ground. Novo Nordisk's ability to stay atop a market that analysts see growing to $150 billion in annual sales is now in doubt. Its controlling shareholder this month forced a surprise ouster of the company's chief executive, Lars Fruergaard Jørgensen. And while it is still generating multibillion-dollar sales for Ozempic and Wegovy, shares have tumbled more than 50% over the past year. If Novo Nordisk doesn't turn things around, it could join a long list of companies that blew a first-mover advantage, from Sunshine Biscuits—whose Hydrox cookies were overtaken by now-iconic Oreos—to the Myspace social network. 'Everyone wants to be the first footprints on the empty beach,' said Americus Reed, marketing professor at the Wharton School of the University of Pennsylvania. 'But it depends on how you land on that first move. The second mover is watching them make mistakes. You're able to identify those and not make those mistakes.' A Novo Nordisk spokeswoman said the company remains the global-volume market leader in GLP-1 drugs, serving nearly two-thirds of patients taking them for diabetes and obesity. Some investors and industry watchers say Novo Nordisk's troubles stem from a cautious, reactive approach starting when the market first burst onto the scene, in contrast with a faster, more aggressive tack in production and marketing by Lilly. 'Novo is always a step behind,' said Yuri Khodjamirian, chief investment officer at Tema ETFs, which owns Novo Nordisk shares. One of Novo Nordisk's early stumbles was underestimating the demand for Wegovy—the weight-loss version of semaglutide, the same compound as diabetes drug Ozempic—ahead of its 2021 launch. The company's planning was informed by its experience generating modest sales for an earlier weight-loss drug, Saxenda. Doctors were skeptical of it, and many health-insurance plans in the U.S. didn't cover weight-loss drugs. Novo Nordisk thought Wegovy might run into the same market constraints as Saxenda, so the company planned modest production levels, using a combination of in-house and contract manufacturing capacity. It wasn't enough. It took only five weeks for the prescription rate of Wegovy to exceed the level that Saxenda had taken five years to reach. Jørgensen recalled later, in an interview in 2024, that he initially thought: ''That's patients who've been lined up, there's pent-up demand, it will normalize.' It didn't. It just kept growing.' The company responded by limiting demand—the last thing a drugmaker wants to do with a new product. Sales representatives asked doctors not to start new patients. The company resorted to rationing by withholding the lower, starter doses for new patients, to conserve supplies for existing patients taking the higher doses. The shortages opened the door for competition. They made it legal for special pharmacies in the U.S. to make compounded, copycat versions of semaglutide that sold for much less than list prices for Ozempic and Wegovy. Telehealth firms capitalized on the new, lower-cost supply by hawking the compounded versions, taking away market share from Novo Nordisk. The shortages gave rival Eli Lilly time to catch up. Lilly introduced Mounjaro for diabetes in 2022, followed by Zepbound, a weight-loss version of the same drug, in 2023. Zepbound has been shown in studies to induce greater weight loss than Wegovy, more than 20% of body weight. Although Lilly also encountered shortages due to high demand, it was able to resolve them more quickly than Novo Nordisk. Now, weekly U.S. prescriptions for Lilly's Zepbound have surpassed Wegovy's. Mounjaro still trails Ozempic but is closing the gap. Novo Nordisk has spent billions of dollars trying to expand manufacturing capacity, including an unusual deal last year for its controlling foundation to acquire the contract manufacturer Catalent for $16 billion. The R&D race for future weight-loss drugs also has tilted in Eli Lilly's direction. Lilly has reported favorable clinical-trial data for two closely watched experimental drugs, including a pill version that analysts think could be appealing to people who don't want injections. Novo Nordisk, meanwhile, has had some R&D disappointments, including studies of an experimental combination weight-loss drug dubbed CagriSema. The less-than-expected results of one study sent Novo Nordisk shares plunging more than 20% in one day in December, wiping out nearly $100 billion in stock-market capitalization for the company. Some analysts have cut their sales forecasts for the drug. Lilly has gained an edge on the marketing front as well. The company beat Novo Nordisk to the punch in launching a direct-to-consumer, online service selling weight-loss drugs at discounted cash prices, aimed at people who don't have insurance coverage. And it was first to strike a deal with a big telehealth firm, Ro, to sell a discounted weight-loss drug. Novo Nordisk eventually made similar moves, but months after Lilly. 'They seem to be missing a lot of these kinds of strategic endeavors to help sell into a market that is different from a lot of pharma markets,' said BMO Capital Markets analyst Evan David Seigerman. The Novo Nordisk spokeswoman said the company resolved its shortages before announcing its direct-to-patient service and striking telehealth deals. Novo Nordisk isn't out of the race. The company can still turn things around by leaning into CagriSema, which generated solid weight-loss data even if it missed expectations, and by developing other new drugs that target various segments of the growing market, Seigerman said. More recently, Novo Nordisk has shown signs of being more aggressive. It signed a deal with CVS to make Wegovy the preferred weight-loss drug for members of its drug-benefit plans. Author Hanne Sindbæk, who has written two books about Novo Nordisk, says there has been an eternal tug of war inside the company between those who are guided by values—the idea that the company works for the common good rather than simply to make a profit—and those who run the business. If Novo Nordisk wants to stay in the game, it may have to lean toward the latter in choosing its next CEO. Jørgensen, the outgoing CEO, is still in his role while the company searches for a new chief. His predecessor as CEO, Lars Rebien Sørensen, who is chairman of the foundation that has voting control of the drugmaker's shares, will join the Novo Nordisk board of directors. 'Now they need somebody more business-driven,' Sindbæk said. Write to Peter Loftus at and Noemie Bisserbe at
Yahoo
7 hours ago
- Yahoo
3 Surprising Stocks That Have More Than Doubled in 2025
Hims & Hers Health, FuboTV, and Groupon have all more than doubled in 2025. These companies took very different paths to their stellar year-to-date results. Hims & Hers Health has had to make some major changes to its business in recent months, but it's still positioned for healthy growth. 10 stocks we like better than Hims & Hers Health › This year has had its ups and downs on Wall Street, but some investments are rolling. There are 14 stocks with market caps north of $1 billion that have more than doubled so far in 2025 -- and some of the names will surprise you. Hims & Hers Health (NYSE: HIMS), FuboTV (NYSE: FUBO), and Groupon (NASDAQ: GRPN) -- yes, that Groupon -- are among those 14 stocks that have more than doubled their shareholder money this year. All three have taken entirely different routes to thumping the market this year. After it posted a whopping 183% gain last year, it wouldn't have been shocking to see Hims & Hers Health stock take a breather in 2025. The online healthcare platform that got its start by making it easier for people to secure prescriptions for erectile dysfunction drugs and hair growth treatments blew up last year due to the popularity of its compounded GLP-1 injectables for weight loss. Because Novo Nordisk (NYSE: NVO) was unable to produce Wegovy fast enough to meet surging demand, the Food and Drug Administration put the drug on its official shortage list. That opened up a legal loophole for businesses that operate as compounding pharmacies to produce and sell their own versions of the patented treatment. Hims & Hers cashed in with its own GLP-1 drug, featuring the same active ingredient found in Wegovy and Ozempic -- semaglutide. More importantly, it offered that treatment at more aggressive discounts than Novo Nordisk was putting on the name-brand versions. Hims & Hers Health was doing fine even before it hopped on the GLP-1 bandwagon in spring 2024. Its revenue has risen by at least 65% in each of the last six years. However, the popular new product helped it accelerate its top-line growth in 2024, and it continued to speed up in the first quarter of this year, when revenue more than doubled. This year began with early gains. Late in 2025, incoming President Donald Trump said he would tap Martin Makary to head the FDA. Makary served on the board of a company that also was into GLP-1 compounding, so the market took the view that Hims & Hers' upticks would continue even after Novo Nordisk finished ramping up Wegovy production to a level that could meet patient demand. Matters didn't exactly play out that way. Hims & Hers stock scored an all-time high on Feb. 19, but within weeks, the share price was cut by more than half. Novo Nordisk's production of semaglutide reached the volume necessary to close the FDA loophole, and it seemed as if the semaglutide compounding ride was ending for Hims & Hers and its peers. Then, two things happened that brought investors back. Novo Nordisk cut deals with a small number of telehealth companies, including Hims & Hers, giving them the right to sell discounted monthly subscriptions of Wegovy. Hims & Hers also reported a blowout first quarter earlier this month, and management forecast that the balance of its business outside of compounding would still grow at a healthy 30% clip this year. One of the first stocks to double in 2025 was FuboTV. The company behind the namesake sports-centric live TV streaming service more than tripled in the first week of trading after it struck a transformative deal with Disney (NYSE: DIS). Fubo had just 1.7 million paid subscribers heading into this year, less than 10% of the roughly 20 million households paying for live TV streaming services that digitally recreate versions of the familiar cable or satellite TV bundle. The stock entered this year trading 98% below the peak it touched in late 2020, when management had dreams of turning the company into a streaming platform with an online sportsbook component. Fubo had to fold that hand, but it still had an ace up its sleeve. Disney and two other media giants had been hoping to launch Venu Sports, a monthly subscription service that would bundle content from all of their sports properties -- anchored by Disney's majority-owned ESPN -- into a digital subscription costing $43 a month. But Fubo sued, and last summer, it won an injunction blocking Venu's launch. In a move to clear that obstacle, Disney offered to acquire a 70% stake in FuboTV. The House of Mouse will contribute its larger Hulu + Live TV service -- with 4.6 million subscribers -- to Fubo. Fubo will also receive $220 million from the Venu partners in exchange for dropping its lawsuit. The deal with Disney isn't expected to close until the the first half of next year, but if it falls apart, Fubo would collect another $130 million. It also has access to a $145 million term loan from Disney. Then something amusing happened. Within days of the deal that would give Disney a majority stake in Fubo but keep the smaller company's management in control, the three Venu partners decided not to go through with their digital bundle. Fubo has had its share of growing pains, but it's in an interesting win-win situation here. However, the shares have been meandering along at levels well below those they reached during that initial spike in January. Finally, we have a more conventional doubling chart. Groupon's rise this year can be traced to two specific events: the fourth-quarter earnings report it delivered in early March, and the first-quarter report it released earlier this month. After eight consecutive years of declining revenues, the online discounter of local experiences is starting to turn the corner. Revenue did decline 5% in Q4 2024, but gross billings for its flagship North American business climbed 8%. Its latest report showed even more improvement. Groupon posted a strong and unexpected profit. Analysts now predict it will make a return to revenue growth this year, and that its improvements will accelerate in 2026. Its business model could also prove to be attractive to lead-seeking businesses if the U.S. economy loses steam -- so don't discount this discounter. Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!* Now, it's worth noting Stock Advisor's total average return is 957% — a market-crushing outperformance compared to 167% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Rick Munarriz has positions in Walt Disney. The Motley Fool has positions in and recommends Walt Disney and fuboTV. The Motley Fool has a disclosure policy. 3 Surprising Stocks That Have More Than Doubled in 2025 was originally published by The Motley Fool
